Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Jason A Tye-Din, A James M Daveson, Gautam Goel, Kaela E Goldstein, Holly L Hand, Kristin M Neff, Alina Popp, Juha Taavela, Markku Maki, Jorma Isola, Leslie J Williams, Kenneth E Truitt, Robert P Anderson, RESET CeD Study Group

Research output: Contribution to journalArticleScientificpeer-review

34 Downloads (Pure)
Original languageEnglish
Pages (from-to)446-457
Number of pages12
JournalThe Lancet gastroenterology & hepatology
Volume8
Issue number5
DOIs
Publication statusPublished - 2023
Publication typeA1 Journal article-refereed

Publication forum classification

  • Publication forum level 2

Fingerprint

Dive into the research topics of 'Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study'. Together they form a unique fingerprint.

Cite this